These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 27750463)

  • 1. Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib.
    Poole A; Girard N; Clayton F; Tantravahi SK
    Leuk Lymphoma; 2017 May; 58(5):1258-1261. PubMed ID: 27750463
    [No Abstract]   [Full Text] [Related]  

  • 2. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.
    Molica S; Levato L; Mirabelli R
    Leuk Lymphoma; 2016; 57(3):735-7. PubMed ID: 26337717
    [No Abstract]   [Full Text] [Related]  

  • 3. Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins.
    Ambinder AJ; Hambley B; Shanbhag S; Merrill SA
    Am J Hematol; 2019 Nov; 94(11):E296-E299. PubMed ID: 31400009
    [No Abstract]   [Full Text] [Related]  

  • 4. Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
    Goldschmidt N; Rund D
    Leuk Lymphoma; 2017 Feb; 58(2):498-500. PubMed ID: 27756158
    [No Abstract]   [Full Text] [Related]  

  • 5. Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.
    Saenz-de-Viteri M; Cudrnak T
    Leuk Lymphoma; 2019 Mar; 60(3):842-844. PubMed ID: 30188238
    [No Abstract]   [Full Text] [Related]  

  • 6. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
    Woyach JA
    Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
    [No Abstract]   [Full Text] [Related]  

  • 7. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
    Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
    Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progressive Multifocal Leukoencephalopathy after Ibrutinib Therapy for Chronic Lymphocytic Leukemia.
    Lutz M; Schulze AB; Rebber E; Wiebe S; Zoubi T; Grauer OM; Keßler T; Kerkhoff A; Lenz G; Berdel WE
    Cancer Res Treat; 2017 Apr; 49(2):548-552. PubMed ID: 27456945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.
    Sato R; Jacob J; Gaballa S
    Leuk Lymphoma; 2018 Jul; 59(7):1738-1741. PubMed ID: 29081253
    [No Abstract]   [Full Text] [Related]  

  • 10. Progressive multi-focal leucoencephalopathy among ibrutinib-treated persons with chronic lymphocytic leukaemia.
    Bennett CL; Berger JR; Sartor O; Carson KR; Hrushesky WJ; Georgantopoulos P; Raisch DW; Norris LB; Armitage JO
    Br J Haematol; 2018 Jan; 180(2):301-304. PubMed ID: 27649938
    [No Abstract]   [Full Text] [Related]  

  • 11. Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis.
    Baron M; Zini JM; Challan Belval T; Vignon M; Denis B; Alanio A; Malphettes M
    Leuk Lymphoma; 2017 Dec; 58(12):2981-2982. PubMed ID: 28554246
    [No Abstract]   [Full Text] [Related]  

  • 12. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Tam CS
    Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
    [No Abstract]   [Full Text] [Related]  

  • 13. Infection with ibrutinib in patients with chronic lymphocytic leukemia: How strong is the association?
    Ball S; Vutthikraivit W; Maiti A; Short NJ
    Eur J Haematol; 2018 Sep; 101(3):418-420. PubMed ID: 29791043
    [No Abstract]   [Full Text] [Related]  

  • 14. A simplified prognostic index for chronic lymphocytic leukemia treated with ibrutinib: Results from a multicenter retrospective cohort study.
    Gordon MJ; Sitlinger A; Salous T; Alqahtani H; Churnetski M; Rivera X; Wisniewski P; Cohen J; Patel K; Shadman M; Choi M; Hill B; Stephens D; Persky D; Brander D; Danilov AV
    Leuk Res; 2020 Feb; 89():106302. PubMed ID: 31982152
    [No Abstract]   [Full Text] [Related]  

  • 15. Is HBV prophylaxis required during CLL treatment with ibrutinib?
    Tedeschi A; Frustaci AM; Mazzucchelli M; Cairoli R; Montillo M
    Leuk Lymphoma; 2017 Dec; 58(12):2966-2968. PubMed ID: 28535112
    [No Abstract]   [Full Text] [Related]  

  • 16. High rates of proven invasive fungal disease with the use of ibrutinib monotherapy for relapsed or refractory chronic lymphocytic leukemia.
    Teh BW; Chui W; Handunnetti S; Tam C; Worth LJ; Thursky KA; Slavin MA
    Leuk Lymphoma; 2019 Jun; 60(6):1572-1575. PubMed ID: 30632838
    [No Abstract]   [Full Text] [Related]  

  • 17. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Chemoimmunotherapy should be standard frontline therapy.
    Wendtner CM
    Clin Adv Hematol Oncol; 2016 May; 14(5):336-8. PubMed ID: 27379694
    [No Abstract]   [Full Text] [Related]  

  • 18. Invasive aspergillosis with pulmonary and central nervous system involvement during ibrutinib therapy for relapsed chronic lymphocytic leukaemia: case report.
    Peri AM; Bisi L; Cappelletti A; Colella E; Verga L; Borella C; Foresti S; Migliorino GM; Gori A; Bandera A
    Clin Microbiol Infect; 2018 Jul; 24(7):785-786. PubMed ID: 29427802
    [No Abstract]   [Full Text] [Related]  

  • 19. Ibrutinib (Imbruvica) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2014 Apr; 56(1440):29-30. PubMed ID: 24736247
    [No Abstract]   [Full Text] [Related]  

  • 20. HBV reactivation in CLL patients with occult HBV infection treated with ibrutinib without viral prophylaxis.
    Innocenti I; Morelli F; Autore F; Corbingi A; Pasquale R; Sorà F; Pompili M; Laurenti L
    Leuk Lymphoma; 2019 May; 60(5):1340-1342. PubMed ID: 30730231
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.